Psilocybins & Phencyclidine (PCP)
Psilocybin, the primary psychoactive compound in certain species of mushrooms, exerts its effects primarily through its active metabolite, psilocin. Psilocin acts as an agonist at serotonin 5-HT2A receptors, a mechanism that underlies its hallucinogenic properties. The activation of 5-HT2A receptors leads to increased excitability in cortical pyramidal neurons, particularly in the prefrontal cortex, disrupting normal sensory processing and cognition. This results in altered perception, visual distortions, changes in thought patterns, and emotional variability.
Psilocybin also affects other serotonin receptors, including 5-HT1A and 5-HT2C, further contributing to its complex subjective effects. Functionally, it reduces activity in the default mode network (DMN), a brain network associated with self-referential thought and ego maintenance, which may explain the mystical and ego-dissolving experiences commonly reported with psilocybin use.
Phencyclidine (PCP), originally developed as a dissociative anesthetic, acts primarily as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, blocking the excitatory action of glutamate. This disruption impairs synaptic plasticity and normal cognitive function, leading to dissociation, hallucinations, and altered perception of reality.
In addition to its NMDA antagonism, PCP influences multiple neurotransmitter systems. It inhibits dopamine reuptake and stimulates its release, contributing to its psychostimulant effects and potential for reinforcing behavior.
Furthermore, PCP interacts with sigma-1 receptors and has partial agonist activity at opioid receptors, further modulating mood, analgesia, and perception. These complex interactions produce profound alterations in consciousness, including depersonalization, amnesia, and in high doses, states resembling acute psychosis.
The combination of psilocybin and PCP presents a pharmacological interaction with unpredictable and potentially hazardous consequences.
Psilocybin's primary action on serotonin receptors contrasts with PCP’s glutamatergic antagonism, which could lead to a state of excessive neurochemical dysregulation. The 5-HT2A activation induced by psilocybin typically promotes cortical excitation and hyperconnectivity, while PCP’s NMDA blockade results in a profound disruption of normal synaptic communication. This dual mechanism could exaggerate perceptual distortions, cognitive fragmentation, and loss of reality testing, increasing the risk of severe psychotic reactions, paranoia, or extreme dissociation.
Furthermore, the dopaminergic effects of PCP could enhance the likelihood of agitation, delusions, and unpredictable behavior, particularly in individuals predisposed to psychotic disorders. Since psilocybin already has the potential to induce transient psychosis-like experiences in vulnerable individuals, the addition of PCP, which is well-documented to cause prolonged psychotic states, significantly amplifies this risk.
Case reports and anecdotal evidence suggest that combining dissociatives like PCP with serotonergic psychedelics can result in extreme disorientation, aggressive behavior, and prolonged psychotic episodes.
Some pharmacological models suggest that NMDA receptor antagonists can potentiate the effects of serotonergic hallucinogens by disrupting glutamatergic regulation of cortical circuits, leading to a state of excessive excitation that is not easily resolved once the substances wear off. The unpredictability of individual responses, coupled with the long-lasting effects of PCP, makes this combination particularly risky.
All things considered, we recommend avoiding this combination.
Last edited by a moderator: